Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: Single-centre experience

Bone Marrow Transplantation

Volumn 45, Issue 3, 2010, Pages 534-542

  Piana J L ^a   Martino, R ^a   Barba, P ^a   Margall, N ^a   Roig, M C ^a   Valcarcel D ^a   Sierra, J ^a   Rabella, N ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Allo RIC; Antigenemia pp65; CMV disease; CMV infection; CMV quantitative PCR; Reduced intensity conditioning HSCT

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CIPROFLOXACIN; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; STEROID; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN CELL; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYCOSIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK FACTOR; SIBLING; SOLID TUMOR; VIRUS PNEUMONIA; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PHOSPHOPROTEINS; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 77949425167     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.180     Document Type: Article

References (42)

1. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al., Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al., Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756.
3. Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M et al., Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347.
4. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al., High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
5. Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I et al., High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-255.
6. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al., Infectious complications following allogeneic HLAidentical sibling transplantation with antithymocyte globulinbased reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177.
7. Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK et al., Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003; 32: 695-701.
8. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al., Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-1607.
9. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al., Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
10. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
11. Gerna G, Baldanti F, Middeldorp J, Lilleri D. Use of CMV transcripts for monitoring of CMV infections in transplant recipients. Int J Antimicrob Agents 2000; 16: 455-460.
12. Yun Z, Lewensohn-Fuchs I, Ljungman P, Vahlne A. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays. Transplantation 2004; 69: 1733-1736.
13. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
14. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lönnqvist B et al., Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66: 1330-1334.
15. Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F et al., CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 2001; 28: 765-768.
16. Manteiga R, Martino R, Sureda A, Labeaga R, Brunet S, Sierra J et al., Cytomegalovirus pp65 antigenemia-guided preemptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant 1998; 22: 899-904.
17. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al., Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.
18. Perez-Simon JA, Díez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C et al., Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102: 1108-1113.
19. Martino R, Caballero MD, Canals C, Simó n JA, Solano C, Urbano-Ispízua A et al., Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659.
20. Pérez-Simó n JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD et al., Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394-403.
21. Pérez-Simó n JA, Martino R, Caballero MD, Valcarcel D, Rebollo N, de la Cámara R et al., Grupo Español de Trasplante Hematopoyético GETH. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2008; 14: 664-671.
22. Rabella N, Perez JL, Pumarola T. The virology laboratory in cytomegalovirus infection. Current possibilities. Enferm Infecc Microbiol Clin 1997; 15 (Suppl 2): 69-76.
23. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
24. Klein JP, Rizzo JD, Zhang M-J, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915.
25. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011.
26. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J et al., Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78-83.
28. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M et al., Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003; 101: 5053.
29. Solano C, Munoz I, Gutierrez A, Farga A, Pró sper F, García-Conde J et al., Qualitative plasma PCR assay (amplicor CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001; 39: 3938.
30. Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R et al., Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 777-782.
31. Junghanss C, Storb R, Maris MB, Carter RA, Sandmaier BM, Maloney DG et al., Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003; 123: 662-670.
32. Bainton RD, Byrne JL, Davy BJ, Russell NH. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002; 100: 3843.
33. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H et al., Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 801-807.
34. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 214-219.
35. Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y et al., Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 431-434.
36. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P et al., Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060-3067.
37. Kalwak K, Moson I, Cwian J, Gorczynska E, Toporski J, Turkiewicz D et al., A prospective analysis of immune recovery in children following allogeneic transplantation of t-celldepleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors. Transplant Proc 2003; 35: 1551-1555.
38. Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V et al., Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920-927.
39. Ljungman P. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients. J Clin Virol 2006; 35: 493-495.
40. Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C et al., Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6: 2356-2364.
41. Lilleri D, Fornara C, Furione M, Zavattoni M, Revello MG, Gerna G. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 2007; 195: 1062-1070.
42. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J et al., Direct visualization of cytomegalovirusspecific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.